Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis

Clin Case Rep. 2023 Mar 24;11(3):e7067. doi: 10.1002/ccr3.7067. eCollection 2023 Mar.

Abstract

A graded challenge with adalimumab could be safe in case of a delayed allergic reaction to golimumab, after a detailed allergological evaluation and the exclusion of allergic sensitization using skin tests.

Keywords: adalimumab; anti‐TNF agent; delayed reaction to biologic agent; golimumab; hypersensitivity reaction to biological; hypersensitivity to biologic agent.

Publication types

  • Case Reports